Hedge fund investor Sahm Adrangi became known for exposing US listed Chinese companies for fraud and short selling them. The 2003 graduate of Yale with a Bachelors in Economics made “a couple million” doing this in 2011. Since then he has moved on to founding Kerrisdale Capital, an investment management firm that handles hundreds of millions of dollars. Founded in 2009, Sahm Adrangi is the Chief Investment Officer.
After graduation, Sahm Adrangi was an analyst for several successful companies. These included Deutsche Bank, Chanin Capital Partners, and Longacre Fund Management LLC. While at these companies he handled high yield bonds, leveraged buyout finances, bankruptcy and restructuring, as well as a distressed debt fund worth around two billion USD. At the end of 2008, Longacre had $1.2 billion in assets under their management.
Sahm Adrangi is known for short selling, but is also talented with long game investments. Kerrisdale was recently able to raise around one hundred million dollars in a first of its kind co-investment fund. The money was raised to bet against a company. Adrangi has a successful history of researching companies and showing the world the shortcomings and problems they are trying to hide. Kerrisdale is seen to be one of the first firms that practice soft activism investing, which means by purchasing large amounts of a company’s stock they are able to enact change from within the company by essentially purchasing seats on their board.
He has a special expertise in the areas of telecommunications, mining, and biotechnology. He has predicted the failure of several drugs in recent years based on their poorly done research and purposely misleading study results. This practice not only helps turn a profit for himself and his other hedge fund investors, but it prevents patients from potentially risking their lives by trying medication that just won’t work.